BiotechTube

nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BID

Phase 2/3Completed
0 watching 0 views this week📈 Rising
60
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prurigo Nodularis

Conditions

Prurigo Nodularis, Nodularis Prurigo, Prurigo, Pruritus

Trial Timeline

Mar 1, 2015 → Aug 1, 2016

NCT ID
NCT02174419

About nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BID

nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BID is a phase 2/3 stage product being developed by Trevi Therapeutics for Prurigo Nodularis. The current trial status is completed. This product is registered under clinical trial identifier NCT02174419. Target conditions include Prurigo Nodularis, Nodularis Prurigo, Prurigo.

Hype Score Breakdown

Clinical
22
Activity
15
Company
5
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT02174419Phase 2/3Completed

Competing Products

20 competing products in Prurigo Nodularis

See all competitors
ProductCompanyStageHype Score
Vixarelimab + PlaceboKiniksa PharmaceuticalsPhase 2
47
UpadacitinibAbbVieApproved
85
Pimecrolimus + Hydrocortisone + PimecrolimusNovartisPhase 2
52
Rocatinlimab + PlaceboAmgenPhase 3
76
AbrocitinibPfizerPhase 2
51
Dupilumab SAR231893 (REGN668)SanofiPre-clinical
22
DupilumabSanofiPhase 3
76
DupilumabSanofiPre-clinical
22
DupilumabSanofiPre-clinical
22
Ruxolitinib Cream 1.5%IncytePhase 1
30
Ruxolitinib Cream + Vehicle CreamIncytePhase 3
74
INCB054707 + PlaceboIncytePhase 2
49
Povorcitinib + PlaceboIncytePhase 3
74
Povorcitinib + PlaceboIncytePhase 3
74
Ruxolitinib Cream + Vehicle CreamIncytePhase 3
74
CDX-0159 + Normal salineCelldex TherapeuticsPhase 1
28
barzolvolimabCelldex TherapeuticsPhase 2
47
nalbuphine HCl ERTrevi TherapeuticsPhase 2/3
60
Nalbuphine ER Tablets + Placebo TabletsTrevi TherapeuticsPhase 2/3
60
serlopitant + PlaceboVyne TherapeuticsPhase 2
44

Other Products from Trevi Therapeutics

nalbuphine HCl ERPhase 2/3
60
nalbuphine HCl ERPhase 2/3
60
nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Placebo tablets BIDPhase 2/3
60
Nalbuphine ER Tablets + Placebo TabletsPhase 2/3
60
NAL ER + Placebo + NAL ER + NAL ERPhase 2
47